Background. Platelet to lymphocyte ratio (PLR) has been demonstrated as a risk and prognostic marker in many of cardiovascular diseases. A relationship between PLR and severity of carotid stenosis has been shown. The aim of our study was to investigate the relationship between PLR and all cause mortality in patients with carotid arterial disease.Methods. This retrospective study included 146 patients who had been performed selective carotid angiography. Carotid stenosis were graded by the North American Symptomatic Carotid Endarterectomy Trial (NASCET) criteria. Platelet to lymphocyte ratio was calculated as the ratio of platelets to lymphocytes. The end point of the study was all-cause mortality.Results. During median follow-up of 16 months (0-65 months) 15 (10.3%) patients suffered all-cause mortality. 50 patients (34.2%) underwent carotid endarterectomy and 69 patients (47.3%) had non-carotid cardiac surgery. 38 patients (26.02%) had cerebrovascular events (stroke/transient ischemic attack) at admission. NASCET grades were not different between survivors and nonsurvivors. Non-survivors had significantly lower hemoglobin (Hb) levels (12.7 ± 1.6 g/dL vs. 13.7 ± 1.7 g/dL, p = 0.031) and they were older than survivors (74.2 ± 8.4 years vs. 68.6 ± 8.5 years, p = 0.029). Non-survivors had significantly higher PLR values compared with survivors (190.3 ± 85.6 and 126.8 ± 53.8, p = 0.017). In multivariate analysis, only PLR predicted all-cause mortality in patients with carotid artery stenosis.Conclusion. In our study, higher PLR was associated with increased all-cause mortality.
Fundamento: O aneurisma do ventrículo esquerdo (AVE) é uma importante complicação do infarto agudo do miocárdio (IAM). Objetivo: Investigar o papel da porção N-terminal do pró-hormônio do peptídeo natriurético do tipo B (NT-proBNP) para predizer o desenvolvimento de AVE após infarto agudo do miocárdio com supradesnivelamento do segmento ST (IAMCST). Métodos: Incluímos prospectivamente 1519 pacientes consecutivos com IAMCST. Os pacientes foram divididos em dois grupos de acordo com o desenvolvimento de AVE nos seis meses após o infarto do miocárdio. Os pacientes com ou sem AVE foram examinados para determinar se existia uma relação significativa entre os valores basais do NT-proBNP e as características clínicas. Um valor de p < 0,05 foi considerado estatisticamente significativo. Resultados: O AVE foi detectado em 157 pacientes (10,3%). O nível basal do NT-proBNP foi significativamente maior em pacientes que desenvolveram AVE após IAM (523,5 ± 231,1 pg/mL vs. 192,3 ± 176,6 pg/mL, respectivamente, p < 0,001). Os preditores independentes da formação de AVE após IAM foram idade > 65 anos, tabagismo, classe Killip > 2, cirurgia de revascularização miocárdica anterior, insuficiência cardíaca pós-infarto do miocárdio, fração de ejeção do ventrículo esquerdo < 50%, falha de reperfusão, fenômeno de no-reflow, pico de troponina I e CK-MB e NT-proBNP > 400 pg/mL na internação. Conclusões: Nossos achados indicam que o nível plasmático do fragmento N-terminal do peptídeo natriurético tipo B na admissão, entre outras variáveis, fornece informações preditivas valiosas sobre o desenvolvimento de AVE após o IAMCST agudo.
ObjectiveTo determine the relationship between spot urine total protein-to-creatinine ratio (TPCR) and albumin-tocreatinin ratio (ACR) in diabetic and/or hypertensive patients with estimated glomerular filtration rate (eGFR) greater than 60 ml/min/m² and to determine the optimal TPCR value that can predict microalbuminuria.
Methods190 diabetic and/or hypertensive patients who had eGFR ≥ 60 ml/min/1.73 m² were studied. Urine dipstick test, spot urine TPCR and ACR values of the patients were evaluated.
ResultsA strong positive correlation was found between ACR and TPCR (p<0.001; r=0.565). The optimal cut-off value for TPCR was 119 mg/g. Sensitivity, specificity and AUC for this cut-off value were 83%, 69% and 0.811, respectively. According to the dipstick test, only 20.9% of the patients had microalbuminuria in the urine protein negative group.
Aim: Studies have found the association of Helicobacter Pylori (Hp) seropositivity with cardiovascular diseases and it has been shown that chronic inflammation with Hp may be related to early atherosclerosis. The aim of this study is to evaluate the relationship between Hp positivity detected by endoscopic gastric biopsy and arterial stiffness. Material and Method: In this cross-sectional study, patients were divided into 2 groups as Hp positive (n=48) and Hp negative (n=61) according to endoscopic gastric biopsy findings. Augmentation index, arterial stiffness and central blood pressure were measured using Pulse wave velocity analysis/Ambulatory blood pressure monitoring in all patients. Result: Augmentation index was significantly higher in the Hp positive group (p=0.020). There was no correlation between central blood pressure and augmentation index and the intensity of Hp colonization (p=0.070, r=0.263). However, logistic regression analysis revealed that positive Hp (OR: 3.593, 95%CI: 1.341-9,629, p=0.011) was the only variable predictive for an augmentation index > 24.9 among variables including, age, BMI, systolic and diastolic blood pressure, central blood pressure, glucose, creatinine, total cholesterol, C-reactive protein, and positive Hp. Conclusion: Helicobacter Pylori positive patients with confirmed biopsy have an increased arterial stiffness. Moreover, presence of Hp infection is predictive for an increased arterial stiffness. Regarding the diversity and frequency of Hp worldwide long term follow up studies with larger sample size are needed to elaborate the mechanism of this relationship.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.